Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
It was allot more quiet than this few weeks ago. The company is going through allot of changes,take time for people to see potential. Pretty busy the other day. Morning.
Premaitha Health (NIPT) This will be the new EPIC for the current company. The name change should happen on Friday after voting on Thursday.
when the share are consolidated,then the current price share price would be 16P,the share price would have to rise to 50p before options could be used,so we would have to go up by over %200. They have a incentive to make this work.
There a shell that did a reverse take into Premaitha & have a new director,the clown who was in charge is gone. Premaitha Health is a molecular diagnostics company employing next generation DNA analysis technology to develop, manufacture and sell molecular diagnostic products intended to have a major beneficial impact on human health. Premaitha is responsible for the development, manufacture and commercialisation of their diagnostic products and works with partners to provide the instrument platforms needed by its laboratory customers. Premaitha Health was established in 2013 and is located on Manchester Science Park, Manchester, UK. Premaitha’s first product is the IONA® test which is the first CE marked non-invasive in vitro diagnostic product for prenatal screening. The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha’s clinical laboratory customers to perform the test in their laboratory, using existing clinical workflow. A fundamental element of the IONA® test is exceptional technical support and customer service. The IONA® test is non-invasive, simple and accurate, and is designed to encourage the broad uptake of the technology allowing all pregnant women accurate and safe information about their pregnancy. Premaitha is built upon a wealth of diagnostic expertise with an experienced management team, scientific and technical excellence and class leading quality management and development systems. Currently focused in the area of non-invasive prenatal tests (NIPT), Premaitha aims to extend its portfolio to cover oncology, personalised medicine and other areas of human health.
Could not agree with your more Ian. However with them attending World Congress they will create more interest & they will no doubt release news how it went some time this week. There is no doubt shareholders will vote in favour of the new deal,after all i doubt any of of who bought in did not buy because of the deal.
Could get news some time this week if they get some interest in there product. 13th World Congress on Fetal Medicine, Nice, France. 29th June – 3rd July 2014. Premaitha is exhibiting at the 13th World Congress on Fetal Medicine. So please visit us on Stand No.1.
The fundraising they has was over subscribed by %400. With less than %45 in public hands,that is less than £2 Million pounds worth of shares. Any good news will make this share move fast.
Not sure where i got 10 for 1. THAT, the Company’s ordinary share capital be consolidated so that every 100 Existing Ordinary Shares held by a Shareholder at the date hereof be and is hereby consolidated into 1 New Ordinary Share.
Ok fair enough,did not read the official document,took the info from another site. Share price would still have to increase by over %200 for directors to use them.
The director has a proven track record of turning companies around. He did a interview on directors talks website. He has been approached by other companies in difficulty & has turned a few down. He will only take on companies which he believes can be saved & allot of potential to grow.
Think you got your decimal point in the wrong place. What i posted was correct. Got it from BrockermanDaniel. Current share price is .16 & not 16P. Your out by %1000. Option price is .5P. Anyone else wish the clarify this? Look at the current share price,what are the chances of it getting to 50p? However with the name change there will be a share consolidation, 10 for 1,so new exercise price will be 5p.
The directors have a incentive for this company to perform,other wise they will not be able to exercise there warrants at .50p. & it must stay above that level for over 30 days. However with they name change there will also be share consolidation 10 for one,so the exercise price will be 5P.
The highly qualified team of scientists and technicians at Premaitha are also currently undergoing IONA® Test development and design verification processes; target completion for this stage is by 30 September 2014. The clinical performance and commercialisation testing is then anticipated to be substantially complete by 31 December 2014 with expected commercial launch of the IONA® test to commence January 2015.
The deal with Premaitha Health will be done & dusted next month,we will then have the name change to Premaitha Health. We have a new director who have a proven track record of turning companies around. Allot should be happening in the coming months.
Biotechnology company Premaitha Health is doubling its Manchester workforce after relocating from Cambridge to tap into the region's talent pool. Share Share Tweet +1 Email Premaithia Health chief executive Dr Stephen Little Biotechnology company Premaitha Health is doubling its Manchester workforce after relocating from Cambridge to tap into the region's talent pool. Premaitha Health, which is led by chief executive Dr Stephen Little, is currently developing an application to carry out prenatal testing to assess whether an unborn baby has Down's Syndrome. Dr Little is a former AstraZeneca scientist who launched and later sold Manchester-based diagnostics specialist firm DxS in an £80m- plus deal to Qiagen, a quoted sampling and testing business, in 2009. He joined Premaitha as chief executive in January and said his immediate task was to relocate to the city to tap into its huge skills set in the science and research sector. He said: “The city has the best knowledge base for science, research and development, and as we took the company from research phase to the development stage, we needed to be in a city which has a growing reputation in the science sector and the skills set to match. “The universities here have a lot of talented people, but the city also has people with experience, which is what we need.” Premaitha currently employs 12 staff in Manchester, but hopes to more than double this to 25, as it looks to commercialise the application - called the IONA. The firm, which is moving to Manchester Science Park next week, will be recruiting technical staff including molecular diagnostic scientists as well as sales and administration staff. It has also been working with MIDAS as it looks to expand its operations. Premaitha is aiming to bring its product to market towards the end of next year. It said the IONA was an advanced testing system compared to the current prenatal screening tests, which can suffer from a lack of accuracy. This can lead to many women with healthy pregnancies being incorrectly identified as “at risk” and subject to invasive follow up tests, which could carry a risk to the foetus. The Premaitha test uses next generation molecular technology to carry out more specific assessment which is safe for the foetus, said Dr Little. He added: “This is very exciting time for the company, which is using leading cutting edge technology in the field of diagnostics to bring the product to market.”
AIM listed Vialogy (VIY) shares came back from suspension on Friday, closing the session at 0.16p after a £6.5 million placing at 0.11p. We took part in that placing and will be taking up our full entitlements in the open offer at 0.11p – we were already shareholders. I suggest that existing shareholders do the same (given how in the money they are already) and also buy a lot more in the market on Monday. Vialogy has bought molecular diagnostic company Premaitha by issuing 95 million shares at 0.11p (that is a £10.5 million price tag). It has raised another £6.5 million at 0.11p in a placing which was FOUR TIMES oversubscribed with a raft of institutions on board. The open offer will raise up to £700,000 more. Effectively the free float (since the vendors and institutions and those who backed the last placing cannot or will not flip) is c 10%, if that. The board now comprises the company rescuer Adam Reynolds, Stephen Little from Premaitha who is a very impressive chap but also David Evans. Do you remember Axis Shield? No wonder the funds were lining up to back this one. Premaitha is working on the final development and commercialisation of a non-invasive pre-natal screening test for Down's syndrome developed by Premaitha. This is a massive market. Assuming the Open Offer is fully taken up the market cap at 0.11p (there will be a 100 for 1 consolidation) is sub £20 million. At 0.15p it is c£27 million and the company will have cash of c£8 million. An £19 million EV for a company with this board set to tap into a market this big ($4.2 billion) looks far too low. This is not a classic value investment of the sort Steve Moore and I favour. There are obvious risks. But we chatted to Reynolds who seems confident that his generous 0ption package (priced at 0.1p) will kick in before very long. That would require the shares to trade at above 0.5p for 30 consecutive days. With an undemanding EV, a tight free float and Evans on board, I really would not bet against it. We will only sell 24 hours after giving Nifty Fifty readers advice to bank gains. Our initial target price is a cautious 0.36p to sell. The stance is strong buy at up to 0.23p. - See more at: http://www.shareprophets.advfn.com/views/5994/vialogy-reverse-takeover-placing-shares-unsuspended-strong-buy#sthash.yH6sB6H6.dpuf
Should see allot more upside from here,the share price is not far from a all time low & is a bargain at this price.
Shares in this company are in short supply. Only %45 in public hands. The company has been transformed before they came out of suspension. I believe they are currently working on a deal right now & news should come soon.
alogy. I’m in for a spin! Posted on June 26, 2014 Brokermandaniel Read all about it.As a general rule of thumb we here at the world’s most infamous, libellous blog don’t usually cover stocks outside of the oil & gas/mining sectors. So it should be a surprise to learn that after slating SOFTWARE & COMPUTER SERVICES AIM listed Vialogy (VIY) shares when the “other lot” were in charge we are now or should I say ‘I have now increased my original token holding” and here’s why. The new improved Vialogy came back from restructuring/suspension a far healthier body politick, the tumour that was killing the Company has been excised. There is new life and where’s there’s life there is hope. Especially when Institutions have piled in en-mass because the new ‘cheeky chappies’ in charge have done exactly what they’ve promised to do here, before, a turnaround, making money for share-holders. The company rescuers are Adam Reynolds, David Evans and Stephen Little from Premaitha. A well-respected triumvirate! Suggest those that are looking for a quick spin. Do their sums. The recent £6.5 million placing at 0.11p. was FOUR TIMES oversubscribed with a raft of institutions now on board. I never took part in that placing because I was too busy with other matters and no one approached me! But I have bought in at a significantly higher price. “Vialogy has conditionally acquired the entire issued share capital of Premaitha, which is a molecular diagnostic company. The consideration of £10.5 million is to be satisfied by the issue of 95,454,545 New Ordinary Shares at a price of 11 pence per share. The Company has raised £6.5 million (before expenses) by means of the Placing and intends to raise up to a further £0.7 million by means of the Open Offer. The net proceeds of the Placing and the Open Offer will be used to develop and commercialize the IONA® Test, a non-invasive pre-natal screening test for Down’s Syndrome developed by Premaitha, and for general working capital purposes. The Acquisition, if completed, is of sufficient size to constitute a reverse takeover under the AIM Rules and therefore is subject to the approval of shareholders at a General Meeting to be held at 11.00 a.m. on 3 July 2014 at the offices of Panmure Gordon (UK) Limited, One New Change, London EC4M 9AF” Premaitha are working on the final development and commercialisation of a non-invasive pre-natal screening test for Down’s syndrome developed by Premaitha. The market for this is very, very large. $4.2 billion. Once the consolidation and proposals go through basically a foregone conclusion Vialogy will have £8,000,000 million in cash. In order for Adam Reynolds to take his options package at 0.1p or 10p post consolidation Vialogy would have to have been trading at above 0.5p or 50p post consolidation for 30 consecutive days. That
Only %45 in public hand,with a Market currently of around £4.3M,thats only £1.93M in private investors hands,that is not allot. On positive news there will be rush for shares which are in short supply. Considering this was over subscribed by over %300 that can mean only one thing,this is going up.